Comprehensive Stock Comparison
Compare CDT Equity Inc. (CDT) vs Innoviva, Inc. (INVA) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Stability / Safety |  INVA | Beta 0.07 vs CDT's 0.34 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | INVA | +29.1% vs CDT's -99.4% |
| Efficiency (ROA) | INVA | 16.6% ROA vs CDT's -237.4% |
Who Each Stock Is For
Income & stability
INVADividend streak 0 yrs, beta 0.07
Growth exposure
INVARev growth 18.5%, EPS growth 8.2%, 3Y rev CAGR 8.7%
Long-term compounding (10Y)
INVA81.4% 10Y total return vs CDT's -100.0%
Sleep-well-at-night portfolio
INVALower volatility, beta 0.07, current ratio 14.64x
Defensive / Recession hedge
INVABeta 0.07, current ratio 14.64x
Business Model
What each company does and how it makes money
CDT Equity is a healthcare company that facilitates the development and commercialization of clinical-stage medical assets. It generates revenue through licensing agreements, milestone payments, and equity stakes in the biotech companies it partners with — typically taking a share of future commercial success. Its key advantage lies in its founders' deep pharmaceutical industry expertise and strategic approach to identifying promising clinical assets with commercial potential.
Innoviva is a biopharmaceutical company that develops and commercializes respiratory therapies for chronic obstructive pulmonary disease (COPD) and asthma. It generates revenue primarily through royalties and collaboration payments from its partnered respiratory drugs — including RELVAR/BREO ELLIPTA, ANORO ELLIPTA, and TRELEGY ELLIPTA — which are commercialized by GlaxoSmithKline. The company's key advantage lies in its long-term royalty streams from established respiratory products and its strategic partnership with a major pharmaceutical company for commercialization.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
INVA 4
CDT 1INVA1/1 metricsCDT1/1 metricsINVA6/6 metricsINVA6/6 metricsINVA2/2 metricsINVA leads in 4 of 6 categories (Financial Metrics, Profitability & Efficiency). CDT leads in 1 (Valuation Metrics).
Financial Metrics (TTM)
INVA and CDT operate at a comparable scale, with $415M and $0 in trailing revenue.
| Metric | CDTCDT Equity Inc. | INVAInnoviva, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $415M |
| EBITDAEarnings before interest/tax | -$17M | $13M |
| Net IncomeAfter-tax profit | -$20M | $271M |
| Free Cash FlowCash after capex | $34M | $195M |
| Gross MarginGross profit ÷ Revenue | — | +78.9% |
| Operating MarginEBIT ÷ Revenue | — | -4.0% |
| Net MarginNet income ÷ Revenue | — | +65.4% |
| FCF MarginFCF ÷ Revenue | — | +46.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +28.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +2.1% | +7.1% |
Valuation Metrics
| Metric | CDTCDT Equity Inc. | INVAInnoviva, Inc. |
|---|---|---|
| Market CapShares × price | $1M | $1.7B |
| Enterprise ValueMkt cap + debt − cash | $8M | $1.1B |
| Trailing P/EPrice ÷ TTM EPS | -0.03x | 6.89x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 11.55x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.67x |
| EV / EBITDAEnterprise value multiple | — | 5.62x |
| Price / SalesMarket cap ÷ Revenue | — | 3.99x |
| Price / BookPrice ÷ Book value/share | — | 1.64x |
| Price / FCFMarket cap ÷ FCF | — | 8.66x |
Profitability & Efficiency
INVA delivers a 23.1% return on equity — every $100 of shareholder capital generates $23 in annual profit, vs $-5 for CDT. On the Piotroski fundamental quality scale (0–9), INVA scores 4/9 vs CDT's 1/9, reflecting mixed financial health.
| Metric | CDTCDT Equity Inc. | INVAInnoviva, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -4.7% | +23.1% |
| ROA (TTM)Return on assets | -2.4% | +16.6% |
| ROICReturn on invested capital | — | +16.8% |
| ROCEReturn on capital employed | — | +12.4% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 4 |
| Debt / EquityFinancial leverage | — | — |
| Net DebtTotal debt minus cash | $7M | -$551M |
| Cash & Equiv.Liquid assets | $554,000 | $551M |
| Total DebtShort + long-term debt | $7M | $0 |
| Interest CoverageEBIT ÷ Interest expense | -15.44x | 11.03x |
Total Returns (with DRIP)
A $10,000 investment in INVA five years ago would be worth $19,748 today (with dividends reinvested), compared to $0 for CDT. Over the past 12 months, INVA leads with a +29.1% total return vs CDT's -99.4%. The 3-year compound annual growth rate (CAGR) favors INVA at 27.3% vs CDT's -98.2% — a key indicator of consistent wealth creation.
| Metric | CDTCDT Equity Inc. | INVAInnoviva, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -50.8% | +14.4% |
| 1-Year ReturnPast 12 months | -99.4% | +29.1% |
| 3-Year ReturnCumulative with dividends | -100.0% | +106.3% |
| 5-Year ReturnCumulative with dividends | -100.0% | +97.5% |
| 10-Year ReturnCumulative with dividends | -100.0% | +81.4% |
| CAGR (3Y)Annualised 3-year return | -98.2% | +27.3% |
Risk & Volatility
INVA is the less volatile stock with a 0.07 beta — it tends to amplify market swings less than CDT's 0.34 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. INVA currently trades 90.4% from its 52-week high vs CDT's 0.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CDTCDT Equity Inc. | INVAInnoviva, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.34x | 0.07x |
| 52-Week HighHighest price in past year | $168.00 | $25.15 |
| 52-Week LowLowest price in past year | $0.58 | $16.52 |
| % of 52W HighCurrent price vs 52-week peak | +0.4% | +90.4% |
| RSI (14)Momentum oscillator 0–100 | 27.2 | 50.8 |
| Avg Volume (50D)Average daily shares traded | 575K | 705K |
Analyst Outlook
| Metric | CDTCDT Equity Inc. | INVAInnoviva, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $32.50 |
| # AnalystsCovering analysts | — | 10 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.3% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 22 | Mar 26 | Change |
|---|---|---|---|
| CDT Equity Inc. (CDT) | 100 | 0 | -100.0% |
| Innoviva, Inc. (INVA) | 100 | 115.65 | +15.7% |
Innoviva, Inc. (INVA) returned +97% over 5 years vs CDT Equity Inc. (CDT)'s -100%. A $10,000 investment in INVA 5 years ago would be worth $19,748 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| CDT Equity Inc. (CDT) | $0.00 | $0.00 | — |
| Innoviva, Inc. (INVA) | $134M | $425M | +218.3% |
Innoviva, Inc.'s revenue grew from $134M (2016) to $425M (2025) — a 13.7% CAGR.
Chart 3P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Innoviva, Inc. (INVA) | 12.1 | 6.1 | -49.6% |
Innoviva, Inc. has traded in a 5x–48x P/E range over 9 years; current trailing P/E is ~7x.
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| CDT Equity Inc. (CDT) | -1.01 | -20.53 | -1932.7% |
| Innoviva, Inc. (INVA) | 0.53 | 3.3 | +522.6% |
Innoviva, Inc.'s EPS grew from $0.53 (2016) to $3.30 (2025) — a 23% CAGR.
Chart 5Free Cash Flow — 5 Years
CDT Equity Inc. generated $-10M FCF in 2024 (-352% vs 2021). Innoviva, Inc. generated $196M FCF in 2025 (-46% vs 2021).
CDT vs INVA: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is CDT or INVA a better buy right now?
Innoviva, Inc. (INVA) offers the better valuation at 6.9x trailing P/E (11.5x forward), making it the more compelling value choice. Analysts rate Innoviva, Inc. (INVA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CDT or INVA?
Over the past 5 years, Innoviva, Inc. (INVA) delivered a total return of +97.5%, compared to -100.0% for CDT Equity Inc. (CDT). A $10,000 investment in INVA five years ago would be worth approximately $20K today (assuming dividends reinvested). Over 10 years, the gap is even starker: INVA returned +81.4% versus CDT's -100.0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CDT or INVA?
By beta (market sensitivity over 5 years), Innoviva, Inc. (INVA) is the lower-risk stock at 0.07β versus CDT Equity Inc.'s 0.34β — meaning CDT is approximately 386% more volatile than INVA relative to the S&P 500.
04Which has better profit margins — CDT or INVA?
Innoviva, Inc. (INVA) is the more profitable company, earning 63.8% net margin versus 0.0% for CDT Equity Inc. — meaning it keeps 63.8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38.5% versus 0.0% for CDT. At the gross margin level — before operating expenses — INVA leads at 72.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — CDT or INVA?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is CDT or INVA better for a retirement portfolio?
For long-horizon retirement investors, Innoviva, Inc. (INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.07)). Both have compounded well over 10 years (INVA: +81.4%, CDT: -100.0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between CDT and INVA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: CDT is a small-cap quality compounder stock; INVA is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.